Start the conversation
What would you do for more of the one commodity
we all want and are quickly running out of…
"We have the means right now to live long enough to live forever." – The Wall Street Journal
"The implications are breathtaking… almost mystical" – MIT Technology Review
"The biggest change in our understanding of biology since the discovery of the double helix." – The New York Times
Hello. My name is Michael Robinson, and I want to ask…
How long do you want to live?
It's not such a strange question when you consider how advances in medicine, antibiotics, new surgeries, prescription drugs… have continuously extended our lives.
But what is the maximum possible lifespan of a human being?
The answer comes from Dr. David Sinclair of Harvard's Genetics Department.
It's going to inspire you to rethink your future, your understanding of mortality, and the very concept of death.
Dr. Sinclair has announced that because of recent medical breakthroughs,
"There is no limit on the human lifespan."
-Dr. David Sinclair, Department of Genetics, Harvard Medical School
His colleagues at Harvard, MIT, Penn, Scripps, and Johns Hopkins have helped develop a treatment that could be the first step toward a permanent cure for mankind's most deadly disease: Aging.
They may have just unlocked our ability to switch on an "immortality gene."
You might be surprised to hear that we've already identified nine species that have a naturally occurring immortality gene.
These animals simply don't age. Some of them you probably know.
Look at the lobster. As they get older, lobsters continue to grow larger, stronger, and more fertile.
Aging is not a death sentence for them.
In fact, there are only two main ways that lobsters can die.
They get eaten by us, or another animal… or they grow so large, their own shell kills them.
Not a pretty picture, I know.
However, it demonstrates that if you removed outside threats, lobsters can nearly achieve immortality.
In fact, there is another animal that already has. It's called Turritopsis Dohrni. It's also known as "The Immortal Jellyfish."
Any time it gets sick or injured, it sinks to the ocean floor, transforms back into a polyp, and reemerges as a newborn.
It biologically turns back the hands of time. Without predators, they would live forever.
Another animal with an immortality gene is the red sea urchin. As it ages, it regenerates damaged parts infinitely.
It never really dies.
This led Dr. Kevin Peterson, a molecular biologist at Dartmouth, to make a very important observation.
"Immortality might be much more common than we think."
– Dr. Kevin Peterson, Molecular Biology, Dartmouth
Dr. Peterson is right.
And here's what's really extraordinary: you and I – we all have an immortality gene hidden inside our DNA.
And, now, thanks to two genetic breakthroughs – both of which have won a Nobel Prize in medicine – and after decades of experimentation and recent human clinical trials…
Doctors have developed a treatment that could allow us to switch our immortality gene on.
So first, we're going to closely examine these breakthroughs.
Then we're going to examine the miraculous treatment that could give us the ability to unlock this immortality gene's potential with as few as four injections.
And besides unlocking our ability to stop aging, these injections could allow our bodies to return to the health and vitality we had in our thirties, and stay there indefinitely.
Imagine never losing a memory or forgetting a face.
Imagine returning to your sexual peak.
Imagine both looking and feeling like you're 30 again.
Now that could all be possible. And that's just for starters.
Clinical tests have already shown that these injections make it possible to reverse the effects of age-related diseases.
Doctors from the Dana-Farber Cancer Center in Boston used it to shrink a patient's liver tumor by 70%. In a 76-man study in Leeds, England, just four injections a year dropped patients' cholesterol levels by 77%. These particular treatments are now being pushed through the FDA's four-phase approval process.
In as little as 24 months, just two years, they could be distributed to medical facilities across North America.
Here's what this all means. If the effects of these breakthroughs are combined, there could be only one way to distinguish the average 90-year-old from a 30-year-old…
Ask them their birthday.
My goal today is to make sure you are at the front of the line when this becomes available. Because it is coming, and it's coming fast.
There is a powerful movement building to get the first of these breakthroughs out as quickly as possible. One company has already received $25 million in advanced research funding for it, and there's another $725 million coming right on its heels.
This deal has given them access to distribution agreements with medical organizations in the United States and 170 countries around the world.
Within the first year of this treatment's release, we could be looking at a $6.2 billion industry.
And from there, it's going to take off.
Each year, the cost of the treatment will come down… and more and more people will be able to access it.
By year three, it could be at the center of an $11.7 billion medical phenomenon. Within five years, when immortality becomes affordable for everyone, it will explode to at least $29.8 billion annually.
And I'm going to tell you about the small lab at the center of this story. Because this is a public company, we're able to explore everything about them.
You'll see exactly what has scientists around the world so excited about the prospect of immortality.
So I'm sure you have a lot of questions, and I'm going to do my best to answer them as quickly as possible.
But before I can show you how you could become biologically immortal, let's first talk about…
Why we die.
When you set aside accidents, trauma, and injuries, seven of the top 10 causes of death in America are all age-related.
And you can trace the root cause of all of these conditions to one specific cellular defect.
So let's take a look at that right now.
What's on your screen is an individual gene.
Genes determine our eye color, our height, the structure of our bodies, literally everything. All of our genes are strung together in a long sequence called DNA.
You've probably seen this before. It's the famous double helix.
Our DNA is extremely fragile, which is why it's enclosed in a protective case: what we call chromosomes. They're in the nucleus of every cell in our body.
Now, let's take a look at the tiny caps on the tips of our chromosome. These are called telomeres.
Their job is to keep the chromosomes tightly wrapped around our DNA so it doesn't mutate. A defect with these telomeres is the primary reason we get weaker and sicker over time.
This is why aging eventually kills us.
Here's how to understand this. As we age, cells die off and are replenished through cytokinesis. Cytokinesis is the process by which cells repeatedly duplicate. They make copies of themselves.
But here's the problem.
Every time your cells duplicate, the telomeres – the protection of your DNA – shrinks just a little bit.
Let's look at the original cell and compare it to one 40 copies down the line.
As you can see, the telomeres in the 40th copy are significantly smaller than the original.
The DNA is exposed. It's almost unprotected.
Because of this defect in our telomeres, human cells can only divide about 60 times before our DNA becomes unreadable. This is why we die.
I'm going to show you my own death.
And I'm going to use a photocopier to do it.
This is a picture of me. I've made one copy.
Now, you can still clearly see my picture in this copy. However, it's a little more degraded than the original.
Now, what happens when, instead of using the original, I take this copied picture and make a copy of it?
This copy of a copy has gotten blurrier. There are more imperfections.
Now, I'm going to repeat this process again and again, taking each new copy and making a copy of it until I have a total of 60.
So, what are you truly witnessing?
I'm fading away.
You are watching me die.
This is what's happening inside of our bodies. As the telomeres on the ends of our chromosomes shrink with each copy that's made, we fade away from our peak.
It's why if you're over 50 like me, you've started having senior moments, because this process has already shrunk your brain by 10-15%.
It's dissolved 30% of the collagen in your skin, which is why it becomes looser and is starting to wrinkle.
It's why your muscle mass has started to melt away, even if you're diligent about exercising, because aging erodes your body's ability to produce growth hormones.
Our vision and hearing falter.
Our bones become more brittle.
Our sex drive slows down.
These are all symptoms that every human experiences as we age.
And, eventually, it's the reason we all die.
So how is it possible that lobsters, sea urchins, jellyfish – at least nine types of animals – never grow biologically older?
What has granted these animals immortality?
And how can we replicate it?
It turns out two biologists at U.C. Berkeley: Dr. Carol Greider and Dr. Elizabeth Blackburn, provided the first part of the answer.
It was hiding in one of these immortal organisms, the Tetrahymena.
In the Tetrahymena, just like in humans, telomeres degrade during cytokinesis.
However, they differ from us in that they have a unique gene switched on. This gene creates a protein called telomerase. After cytokinesis, telomerase goes to work immediately restoring the telomeres to their full length.
The official term for this is immortalization.
When telomerase is present, each cell is immortalized.
It's able to function at 100% full strength, no matter how many times it has copied itself.
The discovery of telomerase earned Dr. Greider and Dr. Blackburn the 2009 Nobel Prize in Medicine.
And here's the good news:
Every cell in your body has this exact immortality gene.
When it's switched on, your cells don't age.
In fact, they become biologically younger.
So, that's the good news.
Unfortunately, there's some bad news that comes along with it.
When we're brought into this world – when we're born – we come with this gene switched off. This is what scientists have been working to reverse.
Now, when I'm talking about a gene being switched on or switched off, here's what I mean.
Let's take a closer look at our cells again.
Inside our cells, we have chromosomes. Encased inside our chromosomes are tightly wrapped coils of DNA.
Now, here's the final piece of the puzzle. It's called RNA.
The job of RNA is to deliver the instructions from our genes to the rest of the cell.
When scientists say a gene is "switched on," what they really mean to say is the gene is creating RNA.
So, when the immortality gene is switched on, that gene starts creating the RNA for telomerase.
Now, before human experiments could be conducted, scientists had to determine that they could switch on the immortality gene in other animals.
Animals that, just like us, were born with it switched off. And they started with mice.
Now, mice don't look much like us, but when you get down to their DNA, we're about 90% similar. Parts of our genome are actually 99% identical.
At the Spanish National Cancer Research Center, doctors successfully switched on the immortality gene in a group of mice. They did it by injecting them with modified DNA, which activated high levels of the telomerase gene.
The normal life span of a mouse is about two years.
However, with telomerase switched on – in other words, with the immortality gene switched on – they lived 40% longer. That's the equivalent of adding an additional 32 years to your life. Not immortality exactly, but a very important first step.
At Harvard Medical School, geneticist Dr. Ronald DePinho led a team that repeated this experiment with almost identical results.
After four weeks of treatment, their conclusions were stunning.
Aged mice had undergone "remarkable signs of rejuvenation."
Their cells experienced a powerful "regenerative response." Muscle tissue was "rejuvenated."
They described what they saw as an "unprecedented reversal of age-related decline."
And Dr. DePinho himself said this was…
"Akin to the 'Ponce de Leon effect.'"
-Dr. Ronald DePinho, Harvard Medical School
If you know your history, that's the explorer who went searching for the Fountain of Youth.
And Harvard is now suggesting they've found it.
But would it work in human cells? The answer is yes.
In a 24-week clinical trial, they used very small levels of telomerase activation. The trial involved 36 men between the ages of 60 and 85.
Just look at these results.
After six weeks, the men's vision has improved by 20%…
At 12 weeks, symptoms of erectile dysfunction were disappearing…
And 24 weeks in, they had a 14% increase in the measurable strength of their immune systems.
By the end of the trial, the men had literally aged backward on a biological level between five and 20 years.
That bears repeating.
By switching on the smallest possible level of telomerase, they turned back the clock on two decades of aging…
And they accomplished this with only six months of treatment.
So, right now, you're probably thinking the same thing as everyone else who hears this.
Michael, if this could help me age backward by two decades, get rid of disease and make me feel like a kid again, why aren't I already on this? Why isn't my doctor prescribing this treatment to me right now?
Well, as you may have guessed, nothing in life comes easy.
There was a catch. And a big one.
Telomerase, the immortality gene, makes all our cells immortal. Unfortunately, not all the cells in your body are healthy.
As you probably know, everyone has some cells with genetic mutations. These mutations create a kind of RNA that leads to cancer, and switching on telomerase makes these cells immortal, too.
It gives them the ability to replicate infinitely.
So, doctors were faced with a paradox.
The cure for aging gave you cancer.
But the truth is, the solution doctors need was already being developed. A new field of medicine called RNA interference, or RNAi, can stop this in its tracks.
Here's a simple way to understand it.
Imagine this glass of water is your body, and you've just received telomerase therapy. So the immortality gene in your cells is switched on.
The problem is one of these cells begins producing cancerous RNA.
Here's what that looks like.
You can't see it happening at first, but these cells are replicating and spreading throughout the body until, all of a sudden, the cancer has taken over.
So, this looks hopeless, right? None of us wants this inside our body.
But with RNA interference, even with the immortality gene active, doctors can neutralize the cancerous RNA.
It's a process called gene silencing.
Doctors identify the cancerous RNA that has corrupted your cells. They then create tiny molecules called small interfering RNA – or siRNA – that are specifically designed to bind to the bad RNA inside the cell and silence their effect.
They take this RNA therapy and inject it into your body. This RNA therapy enters the cells and begins binding to the cancerous RNA, neutralizing its effect.
If all goes according to plan, the cancer is switched off and the body goes back to normal.
The silenced RNA can then be cleaned up harmlessly by the immune system and expelled from our bodies as a waste product.
This is basically how the treatment I've been talking about today works.
So, you've just seen me cure a glass of water. It's a great science trick, but I'm sure what you really want to know is: Will RNA therapy work in human cells?
It turns out that in early 2015, doctors from Stanford proved that in fact it could. They used RNA injections to stimulate telomerase in human cells.
During the initial tests, this RNA therapy reversed the biological age of human skin and muscle by decades, the equivalent of taking a 60-year-old man and making him 35 again. That's like aging 25 years backwards. And not a single cell in the experiment turned cancerous.
I want to repeat that.
There was no cancer.
Just younger, rejuvenated cells.
And it's working faster than any telomerase therapy we've seen in the past.
"We have found a way to turn back the internal clock by the equivalent of many years of human life."
-Dr. Helen Blau, Stanford University
The lead scientist on this project, Stanford microbiologist Dr. Helen Blau, has declared that we can turn back the clock by many years. And all it takes to see this dramatic reversal is just a few days.
In other words, it's possible that…
Human beings can age backwards with no deadly side effects.
RNAi therapy has already been awarded the Nobel Prize in Medicine.
The New York Times reported that it is "the biggest change in our understanding of biology since the discovery of the double helix."
MIT Nobel Prize winner Dr. Phillip Sharp says, "RNAi is the most exciting insight in biology in the past decade or two."
But University of Michigan biochemist Dr. David Engelke probably summed it up best.
"Science has just changed."
And the work at Stanford is just one of dozens of studies being conducted right now.
Doctors at the Dana-Farber Cancer Center in Boston set up an RNAi cancer therapy trial.
They recruited patients with nine different types of advanced stages of tumors. It completely stopped tumor growth in 50% of the patients in the trial.
One of these women – her endometrial cancer tumor actually shrank by 70%. It's been so effective, they've had to keep her on the experimental drug because it's literally saving her life.
And this is just the beginning.
There are currently eight more clinical trials of RNAi's ability to switch off cancer underway. They're being rushed through at medical facilities around the country.
A current projection shows RNAi treatments could hit the market in as little as 24 months. And…
Just one company has become the dominant force in RNAi.
It's not any of the major American pharmaceutical companies. In fact, their genetics division is just 5% the size of Pfizer, and only 3% the size of Johnson & Johnson.
But don't let their size fool you.
They've already formed strategic partnerships with Stanford, MIT, Harvard, the Mayo Clinic, and Scripps.
Their network of doctors includes MDs and Ph.D.s from Penn, Rockefeller University, and Massachusetts General.
They're working with two Nobel Prize winners, a senior scientist from the Human Genome Project, and no less than 12 senior Ph.D.s and MDs leading an army of doctors, geneticists, and biologists.
In the near future, this RNA therapy could notionally be combined with telomerase activations, giving us the ability to wind back the biological clock in each of our cells.
This is something that everyone over the age of 50 needs to know about today, which is why I've prepared a special report called…
Unlocking the Immortality Gene
And I want to rush it to you today for free.
It's going to introduce you to the entire team behind the revolutionary RNA therapy we've been talking about.
You'll see how in clinical trials with human cells, RNA therapy reversed as much as 25 years of aging safely, without creating a single cancer cell.
You'll see how this could be the first in a series of treatments that unlocks human immortality, and I'll show you how to make sure you're at the front of the line when the first RNA therapy reaches the market.
Now, just like any other new treatment, it's going to be expensive. Over $40,000 a year in the early stages.
But that's cheap when you consider it buys you the one commodity we all want more of and simply can't get:
Now, if you're still saying $40,000 is a lot of money, I agree. But I have a solution for that, too.
This report is going to show you a unique investment that could help you cover those costs for this RNA therapy. It's with the lab that pioneered it all.
In these early stages, it's easily one of the hottest investments in the market today. Getting in right now could deliver not two times, not five times, but as much as 12 times your money, and that could be a conservative estimate.
By 2018, the anti-aging market is projected to hit $345.8 billion a year.
But with this RNA therapy, we're not talking about the temporary fixes like hair plugs and wrinkle creams that dominate this market.
We're talking about a treatment that unlocks the ability for your body to become younger on a biological level.
Now, even having said that, I want to be really conservative with our estimates.
So, let's just say this RNA therapy only captures 5% of the existing anti-aging market.
That small slice alone could be worth $17.3 billion a year.
And granting our bodies the ability to switch on our immortality gene is only one application for this RNA therapy. It's already shown an incredible ability to switch off cancer genes.
RNA therapy has stopped the spread of nine different cancers:
- Squamous Cell Head and Neck
- Synovial Sarcoma
- Renal Cell
- Pancreatic Neuroendocrine
- Uveal Melanoma
The market for cancer treatments, the oncology market, is $124 billion a year.
So, let's apply that same conservative 5% estimate that we used for anti-aging.
That's $6.2 billion a year in new revenue.
But it doesn't stop with anti-aging and cancer.
RNA therapy is effective against any disease caused by bad RNA. The same way a small genetic mutation creates the RNA that gives us cancer, a small mutation in a different gene is the root cause of most heart disease.
What causes heart disease? Bad cholesterol.
Fortunately, in advanced clinical trials in Leeds, England, this therapy lowered bad cholesterol by as much as 77%.
And while conventional treatments such as statins can lead to liver damage, muscle weakness, and insomnia, RNA therapy has none – I repeat – none of these side effects.
Heart disease costs Americans $108.9 billion a year. The drugs that manage it are some of the most profitable pharmaceuticals on the market today.
So an RNAi treatment that's more effective will be no different.
But, again, let's stick with a very conservative 5% projection.
That's a brand new $5.5 billion a year revenue stream they can tap into.
And we're not done yet.
An RNAi treatment for hemophilia – that's a genetic disease where blood doesn't clot – in clinical trials, RNA therapy has increased the ability of blood to clot by an average of 138%. The hemophilia market is expected to grow to $11.4 billion a year by 2016. So 5% of that could create…
A new $570 million revenue stream.
Now let's look at Hepatitis C. This is a viral infection in the liver.
After one dose in a clinical trial, RNA therapy removed every measurable trace of the virus in 43% of the participants. Hepatitis C treatments generate more than $5.5 billion a year in revenue.
So again, sticking with a conservative 5% projection, we're looking at a new revenue stream of $273 million a year.
These are only some of the most advanced RNA therapies.
There are at least 15 more in the development pipeline, covering everything from lung and liver disease to rare genetic conditions like Amyloidosis and Porphyria.
Right now, the company making it possible to bring this miraculous RNA therapy to the world? Their entire total portfolio of genetic treatments generates $2.4 billion a year.
But with the conservative estimates I've just shown you, they could be tapping in to a new $29.98 billion a year revenue stream.
That means within two years…
We're looking at revenue growth from RNA therapy alone of 1,141%.
So the windfall profits from investing in this company now could singlehandedly pay for your RNA therapy when it's released.
And in this report, I'll show you everything you need to know about the company, including how to invest in it today.
I want to rush you a copy right now at no cost. All I ask is that you accept an invitation to join me in a unique venture called, the Nova-X Report.
I've spent the majority of my 35-year career in Silicon Valley acting as a board member of one venture capital firm, and as a senior advisor for two more.
I've worked personally with top executives at Boeing, the cutting edge firm Invivo Therapeutics, the cloud computing company Symantec, and alongside household names like Lee Iacocca of Chrysler, Fred Smith of FedEx, and Dave DeWalt of McAfee.
Today, I'm the Director of Venture Capital and Technology Investing here at Money Morning. This has allowed me to launch the Nova-X Report.
The Nova-X Report brings you into my world.
I show you how to get involved with the world's most disruptive technologies as they're being developed.
I'm going to share my research with you, and I'm going to help you claim the financial windfalls only available to early investors.
In other words, I'll help transform you into what I call a Main Street Venture Capitalist. This is a totally different experience than traditional investing.
For instance, last year I gave folks who follow me an exclusive look at one of the most incredible substances on the planet.
It's called living metal.
And it is formed by a gene in the blood of a very rare sea mollusk. This animal only exists in one place on earth, a 14 mile stretch of water off the coast of Southern California.
But its scarcity isn't why it costs $141,748 for an amount that barely fills a thimble.
This is: An international panel of 15 doctors from the University of Liverpool, London's Institute of Neurology, and the Alzheimer's Institute in the U.S. have collectively analyzed this living metal.
They officially concluded it can prevent – and possibly treat – Alzheimer's dementia.
It works by reprogramming our own immune system to attack amyloid beta plaque and flush it out of our body.
If you're not familiar with this plaque, it's an amino acid that binds to your memory receptors.
When it builds up on your brain's hippocampus, it clogs your memory circuits.
This is what causes Alzheimer's.
And this living metal can help eliminate it from our bodies.
Which is why at this very moment, 124 advanced clinical trials are rapidly progressing.
They're taking place at Penn, Baylor, UCLA, and the most cutting-edge medical facilities across the country.
And folks who follow me here were among the first to know about it.
I delivered them a Money Morning prospectus on the one company that controls the only production facility of its kind for this living metal.
I presented them with all of my research. Through my interviews, we talked with the CEO and chief science officer. We virtually toured the heavily guarded facility where this living metal is produced, and we dug into the clinical trials.
According to company projections, revenues from this living metal are expected to surge from $2.63 million in total sales to $620 million a year.
And I showed a group of Main Street venture capitalists how they could purchase stakes in this company before its NASDAQ listing.
Another example is Inovio Pharmaceuticals. Inovio's team has pioneered the development of DNA-based synthetic vaccines for the treatment of the flu, HIV, Ebola, and malaria.
These DNA-based programs have already reached advanced FDA clinical trials.
Again, I took folks behind the scenes on a virtual tour of the company.
They witnessed how this therapy is delivered with a small electric pulse that opens our cells to accept the synthetic DNA treatments.
I shared details of my private meetings with the CEO of this company, Dr. Joseph Kim, and we discussed how Bill and Melinda Gates were bankrolling a part of their operation through the Gates Foundation.
Since then, Inovio's stock has gone up as high as 361%… with plenty more room to grow.
This is what it means to be a Main Street venture capitalist. I'm going to get you in as close to the ground floor as I can on these rare investment opportunities.
It's exactly what I'll deliver to you through the Nova-X Report.
Every month, just like I do for the venture capital firms I work with, I'm going to vet and present you with a new deal.
You'll receive it in a comprehensive research dossier. It will cut through the complex terminology and dissect its technology.
You'll be introduced to the scientists and engineers and walk through exactly what kind of impact this technology could have on the world.
We'll closely examine their books, revenue streams, and profit projections, and I'll show you exactly how to position yourself to capture the historic gains this deal is presenting us with.
This is a new mindset.
No longer will you look at investing as buying stocks. Now you are taking part in venture capital-like deals.
You'll be acquiring pieces of public companies, right as new capital floods in behind a technology that is about to dominate its industry.
This approach is why the team and I here at Money Morning have been able to get folks in early on deals with Celldex, Pharmacyclics, Invivo, Micron, Aegerion Pharmaceuticals, and many, many more.
And I'm really proud of the positive impact I've had on people's lives.
"Michael, you have doubled my money!"
– Alvin Canone
"I made approximately $125k for the year."
– Carter Roberts
"I became a member about a year ago. Since joining you have tripled my net worth."
– Bob Kreen, St. Louis, MO
"Michael, I have a wife and two kids. You have helped my young family recover from the 2008 crisis where we lost everything, including our home. Thanks to you I have been able to rebuild my nest egg."
– Ryan Jared
This is what I'd like to do for you through the Nova-X Report research service.
As soon as you get on board today, I'll send you my special report, Unlocking the Immortality Gene, absolutely free.
It's going to reveal a miraculous medical treatment that in the near future could grant us the ability to unlock biological immortality. It will introduce you to the small lab that is going to bring this to the world.
And just as important, I'll show you how to profit right alongside this company as its revenues surge an estimated 1,141%.
But this report, Unlocking the Immortality Gene, is just the beginning.
Through the Nova-X Report, I want to make sure you have every tool you need to succeed as a Main Street venture capitalist.
So I'm going to do something special. I've set up a series of opportunities – venture capital-like pitches – that I've already vetted for you.
The first I'm calling…
The Nanotech Revolution
This is one of my favorite technologies being developed right now.
There are currently designs for nanotechnology devices the size of red blood cells. These nanobots can be programmed to circulate around your body and clean up any cellular waste they find, and fix damaged cells.
And along with repairing our bodies, they also can be programmed to act just like your normal red blood cells, only much more efficient. They can carry 20 times the oxygen and move faster through the human body.
The current design suggests that when these nanobots are ready, they could allow you to run at full speed faster than you've ever run before.
I'm talking about an Olympic sprint pace for 15 minutes without stopping, or for those same 15 minutes, you could hold your breath underwater without returning to the surface even once.
And it's coming our way, folks.
These devices are being tested right now at MIT. The first generation has just been approved by the FDA, and one small company is behind this.
Right now, their revenue is only $20 million a year. But they're set to dominate what the NEIH has estimated to be a coming $289 billion market, which is why when you join the Nova-X Report today, you'll have immediate access to my in-depth analysis of this technology.
I'll take you on a behind-the-scenes tour of the tiny company who has developed it. You'll meet the scientists and engineers who made it all possible, and we'll review the revenue streams and venture capital investors.
Now, this is not a public company yet, but that's not going to stop us Main Street venture capitalists, because this deal, the opportunity I'll reveal in this report, shows you a way to claim a backdoor stake in the company before it goes public.
Here's another Main Street venture capital deal I've vetted for you.
I call it…
Hans Vestberg, CEO of the world's largest mobile vendor, Ericsson, says there will be 50 billion connected devices on the planet by 2020.
These devices are all wirelessly linked to the same giant network.
You've probably heard of this concept as the "Internet of Everything."
But what you may not have thought about is that these 50 billion devices are also vulnerable points hackers and cyber-criminals can exploit.
So, I'm going to show you the one small firm who is quickly emerging as the global leader in smart device security.
Right now, they have 146 million users worldwide. But by the end of the decade, based on current growth projections, they'll have 1 billion and their stock could shoot up 1,100% while keeping your money, your credit, and your identity completely safe.
Another deal I want to present to you regards…
The Digital Battlefield
In a recent discussion I had with Major General Michael Mazzucchi, he told me point blank the U.S. Army is embedding millions of tiny sensors into their equipment to conquer what I call the digital battlefield.
These special sensors are called microelectromechanical systems, or MEMS. I personally know of highly sensitive military programs that are implementing them. The Air Force is using them for fifth generation fighter sensors.
Another program is called the MQ9 Block 5 Aircraft Program, which uses MEMS for the transfer, encryption, and communication of classified intelligence.
The Dominate in Unmanned Systems program uses MEMS that have been integrated into unmanned underwater, aerial, and ground vehicles to carry out explosive detonation and surveillance assignments.
The budget for these programs is classified, but we do know that the Department of Defense is looking at MEMS as one of their main resources for streamlining operations by $487 billion between now and 2021.
And when it saves the military a lot of money… it could create windfall profits for MEMS producers.
So, in this report, I vet a Main Street venture capital deal that examines the one defense contractor at the center of it all.
Now, let's take a moment to recap everything you will receive as a member of the Nova-X Report.
You're going to immediately receive a free copy of the special report, Unlocking the Immortality Gene (a $99 value)…
Plus an additional series of Main Street venture capital deals I have pre-vetted for you:
- The Nanotech Revolution (a $49 value, yours free)
- Information Lockdown (a $49 value, yours free)
- Digital Battlefield (a $49 value, yours free)
Now, along with these four reports, you will be mailed an exclusive Nova-X Report new member welcome package.
When you open it up, one of the first things you'll see is a special membership card. On it, you will find a phone number you can call to reach our Nova-X VIP concierge team. They'll be able to assist you with your membership, and show you how to capitalize on the unique partnerships we've prearranged for you.
And these are really exciting. For instance, we've arranged a way for you to have on-demand access to more than 40 global trading desks that will allow you to secure stock and market opportunities anywhere in the world.
And here's another benefit. If you are already an advanced trader or want to become one, you will have the ability to access advanced charting software.
You will also be able to purchase CDs and money market funds that pay the highest rates possible.
And if you're a fan of precious metals, you really want to pay attention to this.
As a new Nova-X Report member, you'll have the opportunity to receive both a Silver Eagle coin and Morgan Silver Dollar through one of our special joint partnerships.
These are just a few of the benefits we've unlocked to get you set up.
Then every month in the Nova-X Report, I'll take you behind the scenes to investigate the world's most disruptive technologies… and the companies developing them.
You also will receive access to my video interviews with the CEOs and executives. This way you can get the inside scoop straight from the source.
Every week, I will deliver a technology intelligence briefing where we examine the major stories and trends.
I also have created a central headquarters for everything we're setting out to do with the Nova-X Report. All of the monthly investigations, the weekly briefings, and the video interviews are stored in a private, password-protected Nova-X Report website.
This way you can access everything on your time, 24/7.
The Nova-X Report is a comprehensive solution. It gives you all the tools and resources that you need to become a Main Street venture capitalist, which is why the regular price for a year's subscription is $299.
However, you're not going to pay anywhere near that today.
I've set an ambitious goal for my work here at Money Morning.
I want everyday Americans, not just Silicon Valley venture capitalists, to start cashing in on these life-changing windfalls.
I want you to take that first step toward becoming a Main Street venture capitalist, which is why you can subscribe to the Nova-X Report for only $39.
That's 12 monthly reports, 52 weekly research dossiers, the new member welcome package, unlimited access to the members-only website and concierge service…
Plus of course the special report, Unlocking the Immortality Gene, as well as three additional venture capital-like deals, again: for only $39.
That's more than 85% off the sticker price.
And because I'm so confident that the Nova-X Report can radically enhance your net worth, I'm taking all of the risk for this deal and putting it on my shoulders.
If I don't perform up to your expectations, you aren't going to pay me a single dime.
Here's what I mean: I'd like for you to take the next two months to review everything you receive today.
Examine these investment opportunities and follow along with the weekly intelligence briefings and profit alerts.
But don't stop there.
Review the members-only website, take advantage of the Nova-X Report concierge service, and if for any reason during the next 60 days you feel this isn't right for you, all you have to do is contact me and I'll return every penny of your subscription dues.
And I insist that you keep everything, these four reports, the editions of the Nova-X Report, everything you'll receive during your two-month trial with my compliments.
To join the Nova-X Report, simply click the button below this video.
I want to thank you for taking part in today's presentation and I look forward to working with you.
Copyright – 2015 Money Map Press, LLC. The Money Map Press is a publishing company that does not act as a personal investment advisor for any specific individual. Nor do we advocate the purchase or sale of any security or investment for any specific individual. The proprietary recommendations and analysis we present to readers is for the exclusive use of subscribers. Readers should be aware that although our track record is highly rated, and has been legally reviewed for presentation in this invitation, investment markets have inherent risks and there can be no guarantee of future profits. Likewise, our past performance does not assure the same future results. Warning: The past performance of any trade whether actual or hypothetical is not necessarily an indication of future results. Stocks, futures, currencies, commodities, CFDs, options and all types of investment trading can have large potential rewards, but also carry large potential risks. We make absolutely no representation that gains or losses demonstrated in services published by Money Map Press LLC are likely or achievable. Hypothetical trading examples also cannot possibly take into account the impact of liquidity or buyer and seller demand, and do not allow for slippage and associated trading costs and concerns. One must be aware of the risks and be willing to accept them in order to invest in the markets. One should never trade with money that one cannot afford to lose, and one must accept that there will be losses, and one must be able to sustain these losses, both from a financial as well as an emotional perspective. Recommendations are for the exclusive use of subscribers and can change at any time. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.